Drug Approval | October 01, 2025
AbbVie seeks FDA approval for Pivekimab Sunirine to treat rare, aggressive blood cancer
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
Subscribe To Our Newsletter & Stay Updated